Imatinib mesylate–induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors

Han, Ho Jae; Yu, Yangyang; Wang, Yuhong

doi:10.1016/j.jaad.2008.06.029

Cited by 17 publications

(14 citation statements)

References 43 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case reports in this review suggest that the drug may also result in extraoral pigmentary changes. This correlates with the well‐documented phenomenon of hair and cutaneous depigmentation associated with imatinib therapy, with one article reporting the incidence rate of skin hypopigmentation being between 18% and 40.9%. Hyperpigmentation at extraoral sites is less frequently reported, but there is evidence to suggest imatinib can cause pigmentation of skin, hair and nails.…”

Section: Discussionsupporting

confidence: 61%

See 1 more Smart Citation

Intraoral hyperpigmentation due to imatinib mesylate. A review of the literature

Pancholi

Taneja

2015

Oral Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 61%

“…These include dermatological conditions, ranging from rash to less frequent reports of Stevens–Johnson syndrome and cutaneous pigmentary changes. The latter is more often seen as hypopigmentation, with hyperpigmentation reported less frequently.…”

Section: Introductionmentioning

confidence: 99%

Intraoral hyperpigmentation due to imatinib mesylate. A review of the literature

Pancholi

Taneja

2015

Oral Surgery

View full text Add to dashboard Cite

show abstract

“…Although the mechanism remains speculative, it is thought that depigmentation arises from the loss of MAPK pathway activation, as MAPK pathway is utilized by physiologic c‐KIT‐MITF signaling in promoting pigment production . In contrast, paradoxical hyper‐ or repigmentation with imatinib has been rarely described although the mechanism is not understood . Drug‐induced dark blue‐gray pigmentation thought to be related to hemosiderin deposition has also been reported anecdotally with vandetanib .…”

Section: Mechanism‐based Toxicitiesmentioning

confidence: 99%

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Adjei

2013

CA A Cancer J Clinicians

289

205

View full text Add to dashboard Cite

Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for cancer therapy. Because these proteins are overexpressed or dysregulated in cancer cells compared with normal cells, it was assumed that their inhibitors will be narrowly targeted and relatively nontoxic. However, this hope has not been achieved. Current targeted agents exhibit the same frequency and severity of toxicities as traditional cytotoxic agents, with the main difference being the nature of the toxic effects. Thus, the classical chemotherapy toxicities of alopecia, myelosuppression, mucositis, nausea, and vomiting have been generally replaced by vascular, dermatologic, endocrine, coagulation, immunologic, ocular, and pulmonary toxicities. These toxicities need to be recognized, prevented, and optimally managed.

show abstract

“…In the majority of cases, the pigmentary abnormalities were reversible after dose reduction or drug withdrawal. Localized or diffuse skin depigmentation has been observed in 15-25% of patients [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48], and cases of cutaneous [31,32,37,44,45], nail [40,42,47], or gingival [42,43,47] hyperpigmentation have been described. The fact that such adverse events are relatively frequent and dose-dependent suggests that they are due to a direct pharmacological effect of imatinib.…”

Section: Imatinibmentioning

confidence: 99%

Drug-induced hair colour changes

Ricci¹,

Simone²,

Regno³

et al. 2016

European Journal of Dermatology

View full text Add to dashboard Cite

Drug-induced hair colour changesHair colour modifications comprise lightening/greying, darkening, or even a complete hair colour change, which may involve the scalp and/or all body hair. Systemic medications may cause hair loss or hypertrichosis, while hair colour change is an uncommon adverse effect. The rapidly increasing use of new target therapies will make the observation of these side effects more frequent. A clear relationship between drug intake and hair colour modification may be difficult to demonstrate and the underlying mechanisms of hair changes are often unknown. To assess whether a side effect is determined by a specific drug, different algorithms or scores (e.g. Naranjo, Karch, Kramer, and Begaud) have been developed. The knowledge of previous similar reports on drug reactions is a key point of most algorithms, therefore all adverse events should be recognised and reported to the scientific community. Furthermore, even if hair colour change is not a life-threatening side effect, it is of deep concern for patient's quality of life and adherence to treatment. We performed a review of the literature on systemic drugs which may induce changes in hair colour.

show abstract

Imatinib mesylate–induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors

Cited by 17 publications

References 43 publications

Intraoral hyperpigmentation due to imatinib mesylate. A review of the literature

Intraoral hyperpigmentation due to imatinib mesylate. A review of the literature

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Drug-induced hair colour changes

Contact Info

Product

Resources

About